TABLE 3.
Parameter estimates of the quetiapine final model and bootstrap validations in schizophrenic patients.
| Bootstrap | |||||
|---|---|---|---|---|---|
| Parameter | Estimate | SE (%) | Median | 90% Confidence interval | Bias (%) |
| CL/F (L/h) | 118 | 6.9 | 117 | [100, 130] | −0.85 |
| V/F (L) | 2,460 | 33.5 | 2,505 | [1,222, 5,163] | 1.83 |
| Ka (h-1) | 1.46 (fixed) | — | — | — | — |
| θFLU | −0.536 | 4.7 | −0.535 | [–0.579, −0.487] | −0.19 |
| θDUL | −0.537 | 12.0 | −0.533 | [–0.642, −0.417] | −0.74 |
| ωCL/F | 0.333 | 12.9 | 0.325 | [0.230, 0.410] | −2.40 |
| σ1 | 0.267 | 15.3 | 0.258 | [0.168, 0.327] | −3.37 |
| σ2 | 29.917 | 34.7 | 31.780 | [2.380, 49.785] | 6.23 |
The 90% confidential interval is displayed as the 5th to 95th percentile of the bootstrap estimates. CL/F, apparent oral clearance (L/h); V/F, apparent volume of distribution (L); Ka, absorption rate constant (h-1); θFLU and θDUL are the coefficients of fluvoxamine and duloxetine, respectively; ωCL/F, inter-individual variability of CL/F; σ1, residual variability with proportional error; σ2, residual variability with additive error; Bias, prediction error given as [(median–estimate) × 100% / estimate].